GlassScriptPhysician profile
Mallareddy Maddula
NPI 1487762647
$4,254.27
in general payments reported to CMS, 2019-2025
27 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $212 · 2021: $474 · 2022: $906 · 2023: $356 · 2024: $834 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905 · Education: $21.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.82 |
| Education | $21.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $926.97 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $657.52 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $466.79 | 2019-2025 | Jynarque |
| Amgen INC. | $338.48 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Glaxosmithkline, LLC. | $244.29 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $242.42 | 2019-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $184.82 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $144.46 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $124.49 | 2022-2025 | |
| Akebia Therapeutics INC | $112.32 | 2020-2022 | |
| Nxstage Medical, INC. | $99.73 | 2025 | Nxstage System One |
| Bard Peripheral Vascular, INC. | $94.60 | 2024 | Fluency Endovascular Stent Graft |
| Ardelyx, INC. | $92.18 | 2025 | Ibsrela |
| Horizon Therapeutics Plc | $89.46 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.00 | 2022-2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.39 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $44.71 | 2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $41.90 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $39.40 | 2022-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $36.69 | 2023-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $31.88 | 2024 | |
| Mallinckrodt Enterprises LLC | $30.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.87 | 2019 | |
| Abbott Laboratories | $22.94 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.07 | 2021 | |
| Daiichi Sankyo INC. | $13.58 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallareddy Maddula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.